Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study ( NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results